IRWD Q4 2025 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$629M

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$48M-47.3% YoY

Gross Profit

$47M99.0% margin

Operating Income

$27M56.7% margin

Net Income

-$2M-4.8% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

-60.9%

Cash Flow

Operating Cash Flow

$75M

Free Cash Flow

$75M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$397M

Total Liabilities

$659M

Stockholders' Equity

-$262M

Cash & Equivalents

$215M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$91M	-47.3%
Gross Profit	$47M	$91M	-47.8%
Operating Income	$27M	$31M	-14.1%
Net Income	-$2M	$2M	-200.9%

Revenue Segments

Collaborative arrangement, collaboration and license agreements

$461,000100%

Geographic Segments

North America

$46M98%

Europe and Other

$974,0002%